After completing her BS in molecular biology from Long Island University (LIU) in Brooklyn, NY, Hannah went on to complete her Doctorate of Philosophy in pharmaceutical science, also from LIU College of Pharmacy. During the doctorate program, Hannah was co-educated by Metrum Research Group, where her research project focused on pharmacokinetics in pediatric critical care patients and methodology in evaluating the misspecified model structure. During her internship at Takeda Pharmaceuticals, she performed preclinical translational pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation to support oncology first-in-human dose selection.
Dr. Huang joined Cognigen Corporation in May 2017 as a pharmacometrician, where she participates in various types of PK/PD analysis, with a particular focus on the exposure-response analysis of QTc, in several disease areas such as oncology, psychology, and immunology. She is a current member of the International Society of Pharmacometrics (ISoP).